On September 20, 2023, we received the occupancy permit for the Biotechnology Innovation Center - Onko BCG Plant.
The investment was made in Lublin. The contractor is Karmar.
‘Construction of the Center was an extremely demanding project. It is equipped with the most modern technological line in Europe. The Research and Development Center and the new BCG Onko production plant are our strategic investments, which play an important role in our development plans,’ emphasizes Jakub Winkler, member of the management board of Synthaverse S.A.
Thanks to this investment, it will be possible to improve technologies related to vaccinology in the prevention of tuberculosis and immunology in the treatment of cancer.
‘The Research and Development Center will be used to develop and prepare for the market products that are innovative on an international scale and respond to customer demand, including, among others: a significantly improved BCG vaccine and an improved Onko BCG medicinal product,’ adds Jakub Winkler.
